Arrowhead Pharmaceuticals Hosts Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis

About this update from Arrowhead Pharmaceuticals, Inc.

[{"type":"text","content":" PASADENA, Calif.--(BUSINESS WIRE)--\nArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is hosting a key opinion leader webinar today at 12:00 PM EDT on ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic fibrosis (CF).\n\n\nThe webinar features a presentation by Marcus Mall, M.D., professor and director of the Department of Pediatric Pulmonology and Immunology at The Charité University Medical Center Berlin, who will discuss the current treatment landscape and unmet medical need in treating patients with CF. Arrowhead management is providing a review of the ARO-ENaC program, which utilizes Arrowhead’s proprietary Targeted RNAi Molecule (TRiM™) platform and is the company’s first inhaled RNAi candidate to target pulmonary epithelium. The live webinar and replay may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.\n\n\nKey points discussed on the webinar include the following:\n\n\nMarcus Mall, M.D., professor and director of the Department of Pediatric Pulmonology and Immunology at The Charité University Medical Center Berlin\n\n\n\nThe epithelial sodium channel (ENaC) plays an important role in the pathophysiology of CF lung disease and represents a promising alternative target to improve airway surface hydration and mucus clearance in patients, independent of their CFTR genotype\n\n\nA substantial number of CF patients (without F508del allele) cannot be treated with current CFTR modulators and could benefit from ENaC inhibition\n\n\nPartial rescue of CFTR with current CFTR modulators does not prevent progression of CF lung disease, resulting in an unmet medical need for further improvement of targeted CF therapy\n\n\nENaC inhibition has potential to act synergistically with CFTR modulators by improving the driving force for chloride/fluid secretion mediated by mutant CFTR rescued by CFTR modulators\n\n\nENaC inhibition has potential as a novel therapeutic approach to improve mucus clearance and provide clinical benefits to patients with other muco-obstructive lung diseases, including COPD\n\n\n\nErik Bush, Ph.D., vice president, biology, Arrowhead Pharmaceuticals\n\n\n\nENaC is a well-validated therapeutic target for cystic fibrosis and muco-obstructive lung disease\n\n\nARO-ENaC overcomes critical ...

More updates from Arrowhead Pharmaceuticals, Inc.